Peru: REPEC Issues Communication Related to COVID-19's Impact on Clinical Trial Procedures
March 18, 2020
On March 18, 2020, as a result of the COVID-19 outbreak, the Peruvian Clinical Trials Registry (Registro Peruano de Ensayos Clínicos (REPEC)) issued a communication regarding the current suspension of administrative procedures until March 31.
Clinical trial initiation, maintenance and conclusion must continue under the responsibility of the sponsor, who may implement strategies to protect research participants. Any strategies implemented must be communicated to the National Institute of Health (Instituto Nacional de Salud (INS)) by emailing consultaensayos@ins.gob.pe.